Kumaraguru Raja
Stock Analyst at Brookline Capital
(0)
# 4869
Out of 5,243 analysts
19
Total ratings
25.00%
Success rate
-28.01%
Average return
Main Sectors:
Top Industries:
| Name | Action | Price Target | Current | % Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
Quince Therapeutics | Initiates Coverage On: Buy | 9 | 1.72 | 423.26% | 1 | Dec 18, 2024 | |
Palisade Bio | Initiates Coverage On: Buy | 38 | 1.75 | 2071.43% | 1 | Nov 20, 2024 | |
SAB Biotherapeutics | Initiates Coverage On: Buy | 8 | 3.45 | 131.88% | 1 | Jun 7, 2024 | |
Forte Biosciences | Initiates Coverage On: Buy | 100 | 16.8 | 495.24% | 2 | May 30, 2024 | |
Hepion Pharmaceutica... | Downgrades: Hold | n/a | n/a | n/a | 1 | Dec 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Hold | n/a | n/a | n/a | 1 | Aug 30, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Reiterates: Buy | 150 | 1 | 14900% | 2 | Jul 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Assumes: Buy | 15 | 4.22 | 255.45% | 1 | Jun 29, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Reinstates: Buy | 9 | n/a | n/a | 1 | Mar 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Reinstates: Buy | 21 | 4.25 | 394.12% | 1 | Jan 31, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Reinstates: Buy | 15 | n/a | n/a | 1 | Jan 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Reinstates: Buy | 90 | 25.15 | 257.85% | 1 | Dec 9, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Buy | 29 31 | 0.74 | 4089.19% | 2 | May 18, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Buy | 3360 | 1.38 | 243378.26% | 1 | Sep 21, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Buy | 320 | n/a | n/a | 1 | Mar 30, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Assumes: Buy | 120 | n/a | n/a | 1 | Mar 25, 2021 |